Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| UNITED THERAPEUTICS | 10 | 8 | -1,58 % | ||
| BIOGEN | 9 | 54 | -0,06 % | ||
| ALUMIS | 8 | 2 | -8,78 % | ||
| VOR BIOPHARMA | 8 | - | +0,48 % | ||
| INSMED | 6 | 7 | +3,88 % | ||
| NEUMORA THERAPEUTICS | 5 | 1 | -11,40 % | ||
| AURA BIOSCIENCES | 5 | - | +1,43 % | ||
| AURINIA PHARMACEUTICALS | 4 | - | -3,79 % | ||
| ULTRAGENYX | 4 | - | -1,14 % | ||
| ROYALTY PHARMA | 4 | - | -0,44 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:26 | Kevin Tang uses newfound control of Aurinia to finally take over Kezar | - | FierceBiotech | ||
| 17:22 | Incyte: William Blair belässt Aktie nach Studiendaten auf "Market Perform" | 3 | Investing.com Deutsch | ||
| 17:18 | William Blair reiterates Market Perform on Incyte stock after HS data | 2 | Investing.com | ||
| 17:18 | Jefferies raises United Therapeutics stock price target on trial data | 2 | Investing.com | ||
| 17:18 | Jefferies raises United Therapeutics stock price target on IPF data | 1 | Investing.com | ||
| 17:06 | Teva gains approval of biosimilar of Amgen's Prolia | 4 | Seeking Alpha | ||
| 16:48 | Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy | 1 | Seeking Alpha | ||
| 16:46 | Übernahme durch Aurinia: Aktie von Kezar Life Sciences legt kräftig zu | 3 | Investing.com Deutsch | ||
| 16:42 | BridgeBio stock seen as core holding after muscular dystrophy filing | 2 | Investing.com | ||
| 16:34 | BMO bestätigt Biogen-Rating nach Spinraza-Zulassung und positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 16:34 | Alumis: Leerink bestätigt "Outperform"-Rating nach überzeugenden Studiendaten | 1 | Investing.com Deutsch | ||
| 16:34 | Studiendaten zu Psoriasis-Mittel: Raymond James bekräftigt Kaufempfehlung für Alumis | 1 | Investing.com Deutsch | ||
| 16:30 | BMO reiterates Biogen stock rating on Spinraza approval, trial data | 2 | Investing.com | ||
| 16:30 | Morgan Stanley reiterates Biogen stock Equalweight rating on lupus drug data | 2 | Investing.com | ||
| 16:30 | This Terns Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday | 2 | Benzinga.com | ||
| 16:30 | Raymond James reiterates Strong Buy on Alumis stock after trial data | 1 | Investing.com | ||
| 16:30 | Leerink reiterates Alumis stock rating on consistent trial data | 2 | Investing.com | ||
| 16:26 | Viridian's other rival to Amgen's Tepezza scores phase 3 win, but investors need convincing | 5 | FierceBiotech | ||
| 16:18 | Why Is United Therapeutics Stock Soaring Monday? | 2 | Benzinga.com | ||
| 16:18 | Truist reiterates MannKind stock rating on partner trial data | 2 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.